CliffBio
small molecule

ZELBORAF

VEMURAFENIB

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyHOFFMANN LA ROCHE INC

Drug detail

Brand nameZELBORAF
Active ingredientVEMURAFENIB
Strength240MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2011
Marketing statusRX

Listed patents

PatentExpiresType
9447089June 2032product
8741920July 2030substance, product
7863288June 2029substance, product
7504509October 2026substance, product
8470818August 2026use U-1418
8143271June 2026substance, product

More from HOFFMANN LA ROCHE INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZELBORAF patent cliff — loss of exclusivity June 2032 | CliffBio